What did @jessemarji actually say?
@jessemarji describes SLU-pp-332 as a "fat burning peptide" they're using during competition prep, then walks through dosing (250 to 1000 micrograms), cycle length (10 to 12 weeks on, 2 to 4 weeks off), and claimed benefits including fat burning, insulin sensitivity, and endurance. They also plug a specific vendor with a discount code. The disclaimer is there, but it's thin cover for what is functionally a dosing guide.
To their credit, they temper the hype by calling out the "magic pill" label as marketing language, not their personal belief. That's a better starting point than most TikTok peptide content. But the rest of the video leans hard into specifics that the available science simply cannot support yet.
Does the science back this up?
Mostly, no. SLU-pp-332 is a synthetic ERR-alpha/beta/gamma agonist, developed at St. Louis University. In preclinical research it looks genuinely interesting. But "interesting in mice" is doing a lot of heavy lifting here.
The primary published work comes from Mishra et al. (2023, Journal of Medicinal Chemistry), which showed SLU-pp-332 activated all three estrogen-related receptor isoforms and produced metabolic effects, including increased oxidative metabolism and reduced fat accumulation, in rodent models. A related paper by Murray et al. (2022, Nature Communications) demonstrated that ERR agonism could mimic some effects of exercise on cardiac and skeletal muscle in mice. These are real, peer-reviewed findings. They are not human trial data. There are no published Phase I safety trials, no pharmacokinetic data in humans, and no established therapeutic dose range for people. The dosing numbers in this video came from somewhere, but it was not a clinical study.
What did they get wrong (or right)?
The framing of insulin sensitivity and endurance enhancement as established effects is misleading. Those signals exist in animal data, but presenting them as expected outcomes for human users overstates what is known. The specific claim that 10 to 12 week cycles prevent "receptor desensitization" is speculative. There is no published research on SLU-pp-332 receptor kinetics in humans, so that reasoning is borrowed from other compound classes and applied without evidence.
What they got right: starting at the lowest dose and titrating up is a reasonable harm-reduction principle. Recommending time off between cycles is also sensible, even if the rationale given is not supported by compound-specific data. The acknowledgment that dosing information is scarce online is accurate and at least honest.
The vendor referral with a discount code is the part that deserves the most scrutiny. SLU-pp-332 sold by research chemical suppliers is not pharmaceutical-grade, is not FDA-approved, and has no regulatory oversight for human use. Pointing followers to a specific purchase source while discussing dosing protocols crosses a line that a disclaimer does not erase.
What should you actually know?
SLU-pp-332 is a research compound with no approved human use, no published safety profile in people, and no established dose. The animal data on ERR agonism is legitimately interesting to researchers studying metabolic disease and exercise physiology. That does not make it ready for competition prep cycles.
ERR agonists work on pathways that regulate mitochondrial biogenesis and fatty acid oxidation. Interfering with those pathways without understanding off-target effects, half-life in humans, or interaction with other compounds used in bodybuilding prep is a meaningful unknown risk, not a calculated one. The "start low and go up" advice sounds conservative but is only meaningful when you have a safety floor to start from. Here, that floor does not exist.
If metabolic optimization and endurance are the actual goals, compounds with actual human pharmacology data exist. Discussing those options with a licensed provider is a different conversation than following a TikTok cycle guide for a research chemical with 73,000 views.